Article · 29 Dec 2025
Conference abstractPublished 26 Oct 2015
The economic viability of a US biosimilars industry
Matrix Global Advisors, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Drug manufacturers have recently begun submitting biosimilar applications to the Food and Drug Administration (FDA), leading many to believe that a robust U.S. biosimilar industry and substantial health savings are right around the corner. In this paper, I present an empirical assessment of the viability of biosimilars in the U.S. market and caution against such optimism given biosimilarsâÂ?Â? considerable development costs, moderate expected market share, and diminished profit margins relative to a typical biologic. Federal regulatory burdens (biosimilar naming and clinical testing requirements), statutory burdens (State laws intended to restrict biosimilar substitution could have the effect of hindering market uptake of biosimilars) and natural market risks (payment and coverage decisions by payers) all serve as potential impediments to biosimilar market uptake in the U.S. In this paper, I present the results of a break-even analysis in which I test the economic viability of biosimilars in the United States. This analysis shows that a biosimilar manufacturer would not find it worthwhile to enter the U.S. market for most average (by sales) biologics even under favorable market conditions. Under potential regulatory and market constraints that limit biosimilar market share, only the largest biologics (average annual sales greater than $1.3 billion) are expected to attract biosimilar competition. The paper concludes that adverse decisions by policy makers and effective dissuasion by biologics manufacturers not only may impede biosimilar market share, but may stifle market entry altogether for many products.
Subjects
Business & ManagementAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Bioanalysis & Biomedicine.
Article · 29 Dec 2025
Epigenetic Modifications: Bioanalysis for Disease and Therapeutics
Article · 29 Dec 2025
Advancing Bioanalysis: New Tech, AI, and Precision Medicine
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioanalysis & Biomedicine
- SubjectBusiness & Management
- BylineArticles whose byline prints “Alex Brill”
